FAPi PET/CT Imaging for Prostate Cancer
(FAPI PET Prost Trial)
Trial Summary
What is the purpose of this trial?
This exploratory study investigates how a new imaging technique called FAPI PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with prostate cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors. The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers including prostate cancer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it does mention that you cannot have any new prostate therapy between certain imaging procedures.
What data supports the effectiveness of the treatment FAPi PET/CT Imaging for Prostate Cancer?
Is FAPi PET/CT imaging safe for humans?
How is Gallium Ga 68 FAPi-46 different from other prostate cancer imaging drugs?
Gallium Ga 68 FAPi-46 is unique because it targets fibroblast activation protein (FAP), which can help detect prostate cancer that may not be visible with other imaging agents like PSMA or FDG. This makes it particularly useful for identifying certain types of prostate cancer that are not easily detected by standard imaging methods.12357
Research Team
Jeremie Calais
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center
Eligibility Criteria
This trial is for men with prostate cancer who've had a PSMA PET/CT scan within the last 3 months and are scheduled for surgery or biopsy of their cancer. They must be able to give consent and stay still for up to an hour during imaging.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants receive 68Ga-FAPi-46 intravenously and undergo PET/CT imaging over 20-50 minutes
Follow-up
Participants are monitored for safety and effectiveness after imaging
Treatment Details
Interventions
- Computed Tomography
- Gallium Ga 68 FAPi-46
- Positron Emission Tomography
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jonsson Comprehensive Cancer Center
Lead Sponsor
Prostate Cancer Foundation
Collaborator